Has James Gardner received payments from drug or device companies?

Yes. Drug and device makers reported $1,532 in general payments to James Gardner across 74 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean James Gardner did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about James Gardner come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

James Gardner

Pediatric Endocrinology · Baton Rouge, LANPI 1487824637

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 74 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $908 and has fallen 86.2% since, to $125 in 2025.

$1,532in general payments, 2019–2025

Across 74 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Dexcom, Inc.$307
Medtronic$214
Azurity Pharmaceuticals, Inc.$125
Ultragenyx Pharmaceutical Inc.$121
CSL Behring$105
Insulet Corporation$104
plus $555 from 15 others

What the payments were for

Food & beverage$1,532100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Dexcom, Inc.	15	$307
Medtronic	14	$214
Azurity Pharmaceuticals, Inc.	4	$125
Ultragenyx Pharmaceutical Inc.	2	$121
CSL Behring	5	$105
Insulet Corporation	2	$104
AbbVie	5	$87
Regeneron Healthcare Solutions, Inc.	5	$87
Endo Pharmaceuticals Inc.	3	$49
Grifols USA, LLC	2	$46
Arbor Pharmaceuticals, Inc.	3	$42
Tolmar Pharmaceuticals, Inc.	2	$40
BD	2	$31
Ferring Pharmaceuticals Inc.	2	$28
Lilly USA, LLC	2	$25
Novo Nordisk	1	$25
Companion Medical, Inc.	1	$22
Abbott	1	$20
Xeris Pharmaceuticals, Inc.	1	$19
Tandem Diabetes Care, Inc.	1	$17
Shire North American Group Inc	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

CRYSVITA$106

How this compares

Too few pediatric endocrinology providers in Louisianato place this figure against a meaningful peer group, so we don't.

Other pediatric endocrinology in Baton Rouge

Chantal LutfallahBaton Rouge$2K
Marcela Astudillo JarrinBaton Rouge$1K
Manish RaisinganiBaton Rouge$957
Stuart ChalewNew Orleans$7K
Ricardo GomezNew Orleans$6K
Janna Flint WilsonLafayette$5K
Cielo AlleynNew Orleans$3K
Dania Felipe-RamirezNew Orleans$3K
Sasi PenukondaShreveport$2K
Arlette Soros DupreNew Orleans$2K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →